Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1301-1320 of 1,782 trials

Soft Tissue Sarcoma: Doxorubicin Chemotherapy Study

We are investigating whether adding doxorubicin-based chemotherapy helps patients with high-risk localized soft tissue sarcoma live longer without metastasis. This study compares it to standard treatment to assess safety and effectiveness.

Soft Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

Staphylococcus Aureus Bacteremia: Shorter Antibiotic Treatment

We are studying whether 4 weeks of antibiotic treatment is as effective as 6 weeks for patients with complicated Staphylococcus aureus bacteremia who have improved after initial therapy.

Staphylococcus aureus Bacteremia6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Chronic Myeloid Leukemia: Second Stop of TKI Treatment

We are studying whether patients with CML can maintain remission after stopping their medication for a second time. This trial aims to identify factors that may help in achieving better treatment outcomes.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Rett Syndrome: Testing Mirtazapine

We are studying whether Mirtazapine can improve social behavior, anxiety, and sleep quality in patients with Rett syndrome. This research may help us understand how to better manage symptoms of this condition.

Rett Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

Mucositis in Metastatic Renal Cell Carcinoma: Folic Acid Supplement Study

We are studying whether a folic acid supplement can help reduce mucositis in patients with metastatic renal cell carcinoma receiving targeted therapy. This trial will also assess the impact on quality of life and treatment side effects.

Metastatic Renal Cell Carcinoma≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesInternal MedicineOncology

HIV-1 Control: Genetic and Immune Response Study

We are studying early-treated HIV-1 patients who stopped their antiretroviral therapy to find out if specific genetic and immune markers can predict their ability to control the virus. This research may help improve future treatment strategies.

HIV Positive During Acute Phase>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Gastrointestinal Stromal Tumor: Adjuvant Imatinib Study

We are studying whether adjuvant Imatinib can help prevent cancer recurrence in patients with intermediate-risk gastrointestinal stromal tumors. This trial compares its effects on survival and quality of life against standard treatments.

Gastrointestinal Stromal Tumor>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Ovarian Cancer: Tinzaparin and Biomarkers

We are studying how tinzaparin affects cancer marker levels in patients with advanced ovarian cancer receiving chemotherapy. This trial also looks at the drug's safety and its impact on immune and blood factors.

Epithelial Ovarian Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Myocarditis: Anakinra Treatment Study

We are investigating whether adding Anakinra to standard treatments helps patients with virus-negative myocarditis. This study aims to evaluate its safety and effectiveness compared to usual care.

Virus-Negative Myocarditis6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Decompensated Cirrhosis: New Human Albumin Solution

We are studying a new human albumin solution to see if it is safer and more effective than the standard treatment for patients with decompensated cirrhosis. This research aims to improve clinical outcomes for those needing long-term albumin therapy.

Decompensated Cirrhosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyInternal Medicine

OCTAPLEX for Major Bleeding in Patients on Blood Thinners

We are studying whether a higher dose of OCTAPLEX can effectively stop major bleeding in patients taking direct oral anticoagulants. The trial also looks at the safety of this treatment during emergencies.

Coagulation DisorderAcute Major Bleeding with DOAC Therapy≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesHematology

Preventing Heart Issues in Cancer Patients: Empagliflozin Study

We are studying whether empagliflozin can help prevent heart problems in cancer patients undergoing chemotherapy with anthracyclines. We will compare its effects to a placebo to assess safety and effectiveness.

Cardiotoxicity1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyOncology

Advanced Neuroendocrine Carcinomas: Enfortumab-Vedotin Study

We are studying a new treatment for patients with advanced Neuroendocrine Carcinomas who cannot use standard chemotherapy. The goal is to see if this treatment can help shrink tumors and improve survival.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOncology

Osteogenesis Imperfecta: Losartan Therapy Study

We are investigating the right dose of losartan for older adolescents and adults with Osteogenesis Imperfecta. The study aims to see how it affects bone health and quality of life.

Brittle Bone Disease3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Gout Treatment: Immediate vs. Delayed Febuxostat

We are studying whether starting febuxostat right after a gout attack helps reduce the number of gout days compared to starting it six weeks later. This trial is for individuals experiencing acute gout attacks.

Gout>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOrthopedics and TraumatologyRheumatology

Juvenile Idiopathic Arthritis: Biosimilar vs. Original Medications

We are studying whether switching between biosimilar and original anti-TNF medications helps children with Juvenile Idiopathic Arthritis maintain disease control. The trial will evaluate safety, effectiveness, and the occurrence of side effects.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesRheumatology

Kidney Transplant: Belatacept vs. Anticalcineurins

We are studying whether switching from anticalcineurins to Belatacept improves blood vessel function and reduces arterial stiffness in kidney transplant patients. This may help enhance overall cardiovascular health.

Kidney Transplant>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNephrology

Hydroxychloroquine for Recurrent Pregnancy Loss

We are studying whether Hydroxychloroquine can help women with recurrent pregnancy loss achieve a live birth. The trial also examines pregnancy outcomes and potential complications compared to a placebo.

Recurrent Pregnancy Loss6-12 monthsEfficacy phase (II)Standard MedicinesGynecology and Obstetrics

IVF Success: Exercise and Mediterranean Diet vs. Aspirin

We are studying whether exercise and a Mediterranean diet can improve live birth rates compared to aspirin for women undergoing in vitro fertilization. This research aims to find better ways to support fertility.

Women's Infertility>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyGynecology and Obstetrics

Doxapram for Preterm Newborns

We are studying whether doxapram can safely reduce the risk of death and serious developmental problems in preterm newborns compared to a placebo. This research aims to improve outcomes for these vulnerable infants.

Apnea of PrematurityConfirmation phase (III)Standard MedicinesNeurologyPediatrics